AKT1 and type 2 diabetes mellitus: Capivasertib blocks AKT activity in these tissues, impairing glucose uptake and glycogen synthesis and ultimately leading to hyperglycemia.4,5) Type 1 diabetes is caused by autoimmune β-cell destruction,6) whereas type 2 diabetes is characterized by insulin resistance.7) Thus, capivasertib-induced hyperglycemia more closely resembles type 2 diabetes.